1 A Mixed Methods Study Evaluating Acceptability of a Daily COVID-19 Testing Regimen

- with a Mobile-App Connected, At-Home, Rapid Antigen Test: Implications for Current and
 Future Pandemics
- 4

- 5 Nadia Nguyen, PhD¹
- 6 Benjamin Lane, MPH¹ bvl2110@cumc.columbia.edu
- 7 Sangwon Lee, PhD²
- 8 Sharon Lipsky Gorman³
- 9 Yumeng Wu¹
- 10 Alicia Li4
- 11 Helen Lu, PhD²
- 12 Noemie Elhadad, PhD³
- 13 Michael Yin, MD⁵
- 14 Kathrine Meyers, DrPH*1
- 15
- 16 *Corresponding Author
- 17 Correspondence to kam2157@cumc.columbia.edu
- 18 Aaron Diamond AIDS Research Center
- 19 701 W. 168th Street
- 20 HHSC 1102
- 21 New York, NY 10032
- 22
- 23 Author affiliations
- 24
- 25 ¹ The Aaron Diamond AIDS Research Center, Columbia University
- 26 701 W. 168th Street
- 27 HHSC 1102
- 28 New York, NY 10032
- 29
- 30 ² Columbia University Department of Biomedical Engineering
- 31 1210 Amsterdam Ave
- 32 New York, NY 10027
- 33
- 34 ³ Columbia University Department of Biomedical Informatics
- 35 622 West 168th Street
- 36 PH20 3720
- 37 New York, NY 10032
- 38
- ⁴ Columbia University Vagelos College of Physicians and Surgeons
- 40 630 W 168th Street
- 41 New York, NY 10032
- 42
- 43 ⁵ Columbia University Department of Medicine
- 44 630 West 168th Street
- 45 PH 8 East Room 105
- 46 New York, NY 10032
- 47
- 48

49 Declaration of Interests

- 50 The authors declare that they have no competing interests. NN, BL, MY, and KM are involved in
- 51 completing clinical studies of the COVID-19 antigen test on behalf of BioMedomics Inc. for
- 52 submission to the FDA. SL, SLG, HL, and NE were involved in the development of the paired
- 53 mobile application which has been licensed to BioMedomics Inc. BioMedomics had no role in
- 54 study design, data collection and analysis, decision to publish, or preparation of the manuscript.
- 55 This research did not receive any specific grant from funding agencies in the public,
- 56 commercial, or not-for-profit sectors.
- 57

59 Abstract: (295/300 words)

60

61 Background

- 62 Widespread use of at-home rapid COVID-19 antigen tests has been proposed as an important
- 63 public health intervention to interrupt chains of transmission. Antigen tests may be preferred
- 64 over PCR because they provide on-demand results for relatively low cost and can identify
- 65 people when they are most likely to be infectious, particularly when used daily. Yet the extent to
- 66 which a frequent antigen testing intervention will result in a positive public health impact for
- 67 COVID-19 will depend on high acceptability and high adherence to such regimens.

68 Methods

- 69 We conducted a mixed-methods study assessing acceptability of and adherence to a daily at-
- 70 home mobile-app connected rapid antigen testing regimen among employees of a US-based
- 71 media company. Acceptability was assessed across seven domains of the Theoretical
- 72 Framework of Acceptability.

73 Results

Among 31 study participants, acceptability of the daily testing intervention was generally high, with participants reporting high perceived effectiveness, intervention coherence, and selfefficacy; positive affective attitude; acceptable degree of burden and opportunity cost; and assessing the intervention as ethical. 71% reported a preference to test daily using an at-home antigen test than weekly employment-based PCR. Mean adherence to the 21-day testing regimen was 88% with 43% of participants achieving 100% adherence, 48% testing at least every other day, and 10% testing less than every other day.

81 Conclusions

- 82 Despite overall high acceptability and adherence, we identified three implementation challenges
- 83 that must be addressed for frequent serial testing for COVID-19 to be implemented at scale and
- 84 have a positive public health impact. First, users need guidance on how and when to adapt
- 85 testing frequencies to different epidemiological conditions. Second, users and institutions need
- 86 guidelines for how to safely store and share test results. Third, implementation of serial testing
- 87 strategies must prioritize health equity and protect those most vulnerable to COVID-19.
- 88
- 89 Key words: COVID-19, rapid antigen test, self-test, acceptability
- 90
- 91

92 **1.0 Introduction (5409/5500)**

93

94 The use of at-home rapid COVID-19 antigen tests has been identified as an important public 95 health intervention because such tests provide on-demand results for relatively low cost and can 96 identify people when they are most likely to be infectious. Although antigen tests are not as 97 sensitive as molecular tests like real-time PCR for detecting COVID-19, this limitation can be 98 overcome by testing more frequently, including as often as daily. There is growing evidence from 99 both modeling (1,2) and real-world studies (3–6) that antigen tests used frequently perform as 100 well, and in some cases better at controlling the spread of COVID-19, than PCR administered 101 less frequently.

102

103 Although antigen tests were developed relatively early in the pandemic, with the first at-home 104 antigen test gaining Food and Drug Administration (FDA) approval for use in the United States 105 (US) in December 2020 (Figure 1), they have been unavailable and underutilized for much of the 106 pandemic in favor of more sensitive but also more expensive and time-consuming lab-based PCR 107 tests (7). In contrast, at-home antigen testing is a cornerstone in COVID-19 control measures in 108 many European countries, including the UK and Germany, where such tests have been provided 109 for free or at very low cost and have been widely used (7–9). Recognizing the important role of 110 at-home antigen tests, the Biden administration has taken a number of steps to significantly 111 increase the availability and use of at-home antigen tests, including scaling up production of such 112 tests; investing \$2 billion to distribute free tests throughout the community; selling tests at cost; 113 mailing free tests to households; and mandating tests be reimbursed through insurers (10-12). 114 These steps have the potential to dramatically increase the availability of and access to at-home 115 antigen in the US.

116

117 Yet the extent to which a massive influx of at-home antigen tests to the American public will result 118 in a positive public health impact will depend on whether and how the tests are used. To date, 119 there is limited real-world data on the acceptability of at-home antigen testing, particularly when 120 used serially, where they have been shown to be most effective. Previous implementation studies 121 of numerous evidence-based interventions, particularly those requiring sustained participation 122 and adherence, indicate that acceptability is critical to intervention uptake and success (13–15). 123 Even if at-home antigen tests become widely available, their public health impact will be limited if 124 frequent testing is not acceptable and adopted at scale. To address this knowledge gap, we 125 conducted a mixed-methods study informed by Sekhon's Theoretical Framework of Acceptability 126 (TFA) (16) to evaluate the acceptability of and adherence to a daily testing regimen among 127 employees of a large media company in the US.

128

129 **2.0 Methods**

130

131 2.1 Research Design

132 We conducted a mixed-methods observational study from February-June 2021 to examine 133 factors that influenced the acceptability of and adherence to a serial testing regimen using a 134 self-administered at-home rapid antigen test ("at-home antigen test") in a workplace setting 135 among employees at two divisions of The Walt Disney Company ("Disney"), a media company 136 based in Southern California in the US. This mixed-methods acceptability study was nested 137 within a larger parent study (N=93) testing the effectiveness of a daily testing regimen using an 138 at-home antigen-test against weekly testing with PCR at Disney. Participants in the parent study 139 were mailed at-home COVID-19 antigen test kits to their home address and asked to self-test 140 daily for 21 days and, as a condition of their employment, were also concurrently testing at least 141 weekly for COVID-19 using PCR. In our nested acceptability study, after providing written 142 informed consent, participants were asked to complete a one-time quantitative survey (N=31),

and a subset of participants contributed a one-time qualitative in-depth interview (N=15) at the
conclusion of 21 days of daily testing. Participants had a choice to complete both the
quantitative survey and qualitative interview or just the survey. Participants who completed the
survey were entered into a drawing for a \$100 gift card, and participants who completed the
interview received a \$25 gift card. All study procedures were reviewed and approved by the
Columbia University Irving Medical Center's Institutional Review Board.

149

150 2.2 Recruitment and Study Population

151 Participants in the acceptability study were informed of the goals of the study and recruited from 152 the parent study via email. To be eligible for the parent study, participants were 18 years of age 153 or older; owned a smartphone; understood and read English; had not been diagnosed with 154 COVID-19 in the past 90 days; had not received any COVID-19 vaccine doses at enrollment; 155 and were willing to share their weekly PCR results. There were no additional inclusion criteria 156 for the acceptability study aside from willingness to complete the quantitative survey and being 157 at least 14 days into the parent. COVID-19 vaccinated employees were excluded because at 158 the time of recruitment, vaccination was believed to provide strong protection against 159 breakthrough infections.

160

161 2.3 At-Home Rapid Antigen Test and Mobile App

Participants used an investigational at-home antigen test that is currently under review with the FDA for Emergency Use Authorization. Test results were available to participants after 15 minutes (for test details, see Appendix A) The test also included a paired smart phone mobile application (mobile app) that had the following functions: provided step-by-step testing instructions; captured image of test result and automatically interpret result (positive, negative, invalid; securely store test result history; and transmit daily test result to the study team.

168

169 2.4 Data Collection

170 2.4.1 Theoretical Framework

- 171 The quantitative survey and in-depth interview questions were informed by Sehkon's Theoretical
- 172 Framework of Acceptability (TFA) (16). The TFA defines intervention acceptability as a multi-
- 173 faceted construct that reflects the extent to which people consider the health care intervention to
- be appropriate, based on anticipated or experienced cognitive and emotional responses to the
- 175 intervention. The TFA consists of seven constructs which we adapted to measure the
- acceptability of the intervention: affective attitude, burden, perceived effectiveness, ethicality,
- 177 intervention coherence, opportunity costs, and self-efficacy (Table 3).
- 178
- 179 2.4.2 Adherence to Daily Testing Regimen
- 180 Participants submitted daily test results to the study team by scanning a picture of the test

181 cassette using the mobile app.

182

183 2.4.3 Quantitative Survey

184 Each of the TFA's seven constructs of acceptability was evaluated by one to three statements

185 which participants rated on a five-point Likert scale (strongly disagree=1 to strongly agree=5).

186 As a global measure of acceptability, participants were also asked whether, if given a choice,

they would prefer to test for COVID-19 using the current PCR regimen or test daily with an at-

188 home antigen test. We measured sociodemographic factors, including age, race/ethnicity, sex,

education, living environment, and financial stability. Participants self-administered the 20-

190 minute survey using REDCap, a secure web platform for administering online surveys.

191

192 2.4.4 In-Depth Interview

193 We conducted in-depth interviews with participants to more deeply understand their current and

194 previous COVID-19 testing experiences and the acceptability of the daily COVID-19 testing

195 regimen. The interview guide was designed to assess the seven constructs in the TFA. 196 Interviews were approximately 60 minutes long and conducted over Zoom by a team of four 197 researchers experienced in gualitative interviewing (NN, BL, KM, and YW). Of the four 198 researchers: two identified as Asian cis-gendered females, 1 White cis-gendered female, and 1 White cis-gendered male; all four lived in New York City. All four were employed by Columbia 199 200 University, which made rapid turnaround PCR testing available as needed in addition to random 201 surveillance testing, and all were also using at-home antigen tests in their personal lives. 202 Interviews were summarized in debrief forms immediately after completing the interviews and 203 were audiorecorded and transcribed by a paid transcription service. 204 205 2.5 Data Analysis 206 207 2.5.1 Quantitative analysis 208 We summarized participant characteristics by estimating mean, standard deviation, frequency 209 and proportion for all categorical and continuous sociodemographic and health factor variables, 210 respectively. Additionally, we estimated the mean, standard deviation, median, and interguartile 211 range (IQR) for each TFA construct measure and also estimated the frequency and proportion 212 of participants who stated that they strongly agreed or agreed with each statement. We 213 calculated overall adherence by taking the number of submitted test results and dividing it by 214 the 21 days of the study. We categorized adherence into three groups and estimated the

number and proportion of participants per group: 100% (tested daily), 50%-99% (tested at least

every other day), and <50% (tested less than every other day). Finally, we calculated the

217 frequency and proportion of participants who stated they would prefer testing daily with a rapid

antigen test versus their current PCR regimen if given the choice.

219

220 2.5.2 Qualitative analysis

221 Interview transcripts were analyzed by a team of three researchers in Dedoose using Template 222 Analysis, which is appropriate for studies using a priori themes and exploring perspectives of 223 different groups in an organizational context (17). We initiated data analysis with a top-down 224 approach, using the seven constructs in the TFA to create an organizational template. One 225 member of the research team created a preliminary codebook by reading through interview 226 debrief forms and identifying subconstructs within each of the TFA constructs. With the seven 227 TFA constructs listed as parent codes and the subconstructs as child codes, the initial codebook 228 was applied to two interview transcripts in Dedoose. A second researcher then applied the 229 preliminary codebook to two more interviews and the codebook was further discussed and 230 refined. All three coders then re-coded the initial four interviews using the finalized codebook to 231 maximize reliability across coders. The three coders then individually coded the remaining 11 232 interviews, meeting on an ad hoc basis to resolve coding questions, and using memos to note 233 emerging themes. The coders generated code reports for each TFA construct, identified key 234 quotes for each construct and subconstruct, and held team meetings to discuss emergent 235 themes that conceptualized how each construct either directly or indirectly influenced 236 acceptability and adherence. Lastly, we created quote matrices for each construct and 237 subconstruct using the identified key quotes organized by emergent themes.

238

239 3.0 Results

240

241 **3.1 Participant characteristics**

Of the 63 eligible Disney employees, we enrolled 31 participants who completed the online survey, of whom 15 also agreed to an in-depth interview between February-June 2021 (Table 1, Figure 1). The 15 interview participants were similar to the overall sample of the survey, with regard to sociodemographic and health factors and adherence.

246

247 **3.2 Adherence to daily testing regimen**

- 248 Mean adherence to the 21-day testing regimen was 88% with 43% of participants achieving
- 249 100% adherence, 48% achieving 50-99% adherence, and 10% achieving less than 50%
- adherence (Table 2).
- 251

252 3.3 Testing preference

- Most participants (71%) reported that if given the choice, they would prefer to test for COVID-19 daily using an at-home antigen test than weekly using PCR, while 19% preferred PCR, and 10% preferred only testing when necessary (Table 2).
- 256

257 **3.4 Acceptability of the daily testing regimen**

258

259 *3.4.1 Affective Attitude*

260 Participants reported overall positive feelings about the intervention though only 58% agreed 261 with the statement "I like using the test every day" (see Table 3 for mean and median Likert 262 scale scores). The overwhelming feeling reported by participants was comfort and peace of 263 mind (Table 4, Affective attitude 1). Testing negative gave them needed reassurance to go 264 about their daily lives and participants reported feeling "liberated" to engage in everyday 265 activities without fear of infecting others (Affective attitude 2, 3). Participants also described 266 using the tests after engaging in a "high risk" activity or potentially being exposed to COVID-19 267 (Affective attitude 3). Notably, a small number of participants described significant anxiety due 268 to living with someone who was immunocompromised; for these participants, the ability to test 269 daily or on demand provided significant mental health benefits (Affective attitude 4).

270

For some participants who struggled to incorporate testing into their daily routine or who had difficulty using the mobile app to capture and interpret their test result, daily testing was more

burdensome. In these cases, participants reported feeling dread when they remembered they
still had to test or frustration at being repeatedly unable to scan in a test result through the
mobile app (Burden 6, Opportunity cost 5).

276

277 3.4.2 Burden

278 More than half of participants disagreed with the statements "it is inconvenient to use the self-279 test every day" (61%) (Table 3). Most participants describing daily self-testing as very 280 convenient compared to other testing options they experienced (e.g., large drive-through testing 281 events early in March/April 2020 or mandatory testing offered by their employer). Even among 282 participants who had access to weekly on-site testing at their workplace, most preferred the 283 daily antigen test. These participants overwhelmingly described testing daily as fast and easy 284 often noting that daily self-testing took less time overall than weekly PCR testing (Table 4, 285 Burden 1): that they didn't mind daily testing because they could test on their own schedule and 286 get the results guickly (Burden 2) or incorporate self-testing into other established routines (e.g., 287 timing the 15-minute waiting period with a shower) (Burden 3); and that they did not find the 288 daily swabs to be invasive (Burden 4). While some participants described mild discomfort from 289 the daily swabbing, this was not a major burden.

290

In the minority were participants who acknowledged that while daily at-home antigen testing was
more convenient than weekly PCR testing, they still preferred testing using PCR because of the
mental energy required to self-administer the test (Burden 5). Other participants described
difficulty incorporating testing into their daily routine and reported testing fatigue (Burden 6).

295

296 3.4.3 Self-efficacy

Participants reported that the self-test was easy to learn to use (90%) and results easy to
understand (100%) (Table 3). However, only half of participants (55%) stated that they

299 developed a habit of testing for COVID-19 in their daily routine, with experiences adhering to 300 daily testing varying widely across participants. While some participants reported feeling initially 301 overwhelmed by the testing steps, nearly all reported mastering the steps after a few days of 302 testing (Table 4, Self-efficacy 1, 2). Factors that supported daily adherence included developing 303 strategies to streamline the testing process (Self-efficacy 2); incorporating the test into their 304 daily routine (Self-efficacy 3, 4); and placing the test kit in a prominent location (Self-efficacy 3). 305 In contrast, participants reported that changes to their daily routine and weekends were the 306 greatest barrier to daily adherence (Self-efficacy 5, 6).

307

308 3.4.4 Opportunity Cost

309 Most participants strongly agreed with the statement: "It is easy for me to find a time to use the 310 test every day" (68%) (Table 3). Nonetheless, time was often described as the biggest 311 opportunity cost to testing daily (Table 4. Opportunity cost 1, 2). Some participants attempted to 312 minimize the time cost by multi-tasking (Burden 3) or spreading out the time commitment by 313 setting up their test kit the night before (Self-efficacy 3). However, others reported that efforts to 314 multi-task resulted in more time spent testing because they would lead to mistakes like missing 315 the results window during and having to repeat the testing process again (Opportunity cost 1, 2, 316 3). For other participants, access to strong internet and/or a good light source were additional 317 opportunity costs to daily testing as the mobile app required a specific level of light to accurately 318 interpret the test result (Opportunity cost 4, 5). Participants who struggled to upload a picture of 319 their test result consequently described testing as a "daily hassle" and "frustrating", negatively 320 impacting their affective attitude about the testing regimen.

321

322 *3.4.5 Ethicality*

Most participants agreed that it is ethical for an employer to require its employees to test regularly for COVID-19 (87%) (Table 3). However, a small minority believed that regular testing

325 should be a personal choice (10%) and a significant portion of participants believe that sharing 326 test results should be a personal choice (42%). Many participants articulated how working long 327 hours near other coworkers necessitated the need for routine testing and saw mandatory testing 328 as a practical approach to keeping the workplace safe (Table 4, Ethicality 1, 2). Specifically, 329 many used Utilitarian arguments to justify mandatory testing, saying that the small loss of 330 privacy and autonomy was justified for "the greater good" of workplace safety (Ethicality 3, 4, 5). 331 Others went further, stating that routine testing helped them fulfil their personal responsibility to 332 keep their workplace safe, noting that they "didn't want to be transmitters" and that giving 333 someone else COVID would be "an unacceptable thing" (Ethicality 6). In contrast, a small 334 number of participants believed mandatory workplace testing was not ethical as it infringed upon 335 individual liberties. While these participants were personally willing to test regularly through their 336 employer, they believed that coercive tactics should not be used to keep the workplace safe 337 (Ethicality 7).

338

339 While participants tended to feel strongly that requiring regular COVID-19 tests was either 340 ethical or unethical, participants' feelings about who should have access to test results and what 341 this health information should be used for was more nuanced. Many agreed that test results 342 should be reported to their employer to prevent the spread of infection should an employee test 343 positive (Ethicality 8); however, some had concerns about who within their company should 344 have access to results (Ethicality 9). Participants also had mixed feelings regarding whether 345 COVID-19 test results should be shared with larger health organizations, such as state health 346 departments or the Centers for Disease Control and Prevention (CDC). Most participants 347 believed these were trusted entities and saw the benefit of sharing COVID-19 results for 348 contract tracing, surveillance, and allocation of health services (Ethicality 10); however, this 349 feeling was not universal, and some reported not trusting the CDC or worrying that the health 350 department would limit their freedom if they tested positive (Ethicality 11, 12). Additionally, a

small number of participants believed test results should stay within their employer due to
concerns about health information privacy, including fears that their health information could be
sold or compromised (Ethicality 13, 14). At the same time, many participants liked the idea of
their test results being automatically reported to their employer or doctor through a mobile app,
as this would eliminate the need for a third party to handle test results (Ethicality 15).

356

357 *3.4.6 Coherence*

358 The majority of participants believed that testing for COVID-19 daily made sense to prevent the 359 spread of COVID-19 at and beyond the workplace (77%) (Table 3). Support for daily testing was 360 particularly strong for times when COVID-19 rates were increasing or high; in this context, 361 regular testing was considered an effective and necessary strategy for monitoring infection rates 362 and preventing COVID-19 transmission (Table 4, Coherence 1). Specifically, many participants 363 believed the unique needs of the entertainment industry, which relies on non-replaceable people 364 to fill specific roles, further necessitated a stricter approach to COVID-19 control to ensure that 365 work would not be disrupted (Coherence 2). Many participants said they wish they had access 366 to daily testing during the original peak of the pandemic in March and April of 2020 (Coherence 367 3).

368

369 While support for regular testing was near universal during times when risk of COVID-19 370 infection was perceived to be high (i.e., before vaccines were available, when rates of infection 371 were still increasing), there was less agreement about when routine testing was no longer 372 needed. Many participants thought it made sense to continue regular COVID-19 testing until 373 there was more research available on the transmissibility of emerging COVID-19 variants and 374 effectiveness of the COVID-19 vaccines (Coherence 5). Others preferred to listen to scientific 375 recommendations from public health agencies to decide whether frequent testing made sense 376 (Coherence 6). Some participants expressed increasing doubt that regular COVID-19 testing

377 was still necessary given that vaccines were widely available to all adults and rates of COVID-378 19 in the workplace and surrounding community were very low (Figure 1). One participant in a 379 managerial position used a cost benefit analysis to argue that frequent testing did not make 380 sense from a financial perspective given the low positivity rates (Coherence 7). Many believed 381 testing did not make sense for vaccinated populations, but that it may be an alternative for those 382 who did not wish to become vaccinated (Coherence 8).

383

384 3.4.7 Perceived effectiveness

385 Participants had high confidence in the effectiveness of a daily testing intervention with the 386 majority reporting that they trusted the results of the at-home antigen test (81%) and nearly all 387 expressing confidence that testing daily will keep the people they work with safe from COVID-19 388 (90%) (Table 3). Whether participants perceived the daily testing intervention would keep the 389 workplace safe depended on three factors: 1) whether they trusted the test results, 2) whether 390 they believed their co-workers would be willing and able to test daily, and 3) whether they 391 believed frequent testing would introduce any unintended consequences. Although the antigen 392 test used in the study had not yet received FDA approval and was only for use in research 393 settings, nearly all participants reported trusting the results, citing trust in Columbia University 394 (which helped develop the test in collaboration with a biotechnology company), trust in Disney 395 (their employer) to provide a safe and effective test, and trust in experts/scientists (Table 4, 396 Perceived effectiveness 1, 2). Other participants drew on previous experience using similar at-397 home tests (e.g., home pregnancy tests, glucose monitoring, maintaining swimming pool pH) as 398 reasons for trusting the results (Perceived effectiveness 3). One participant noted that they 399 trusted the daily antigen test result more than weekly PCR because the antigen test result 400 reflected current COVID-19 status while the PCR result reflected a status from 24-48 hours ago 401 and could give a false sense of security (Perceived effectiveness 4). In contrast, a different 402 participant reported trusting the antigen test result less than PCR because they had heard from

family and friends with medical training that antigen tests were not as accurate as PCR(Perceived effectiveness 5).

405

406 While participants were generally confident in their own ability to successfully use the at-home 407 antigen test, they were less confident about their co-workers' abilities, which they believed could 408 undermine the effectiveness of the daily testing intervention. These concerns included not 409 believing that their coworkers would obtain a sufficient swab sample and properly self-410 administer the test at home (Perceived effectiveness 6), believing that a test administered by a 411 medical professional would be more accurate (Perceived effectiveness 7), and worry that the 412 identity of the test taker and the test result could not be confirmed in a home setting (Perceived 413 effectiveness 8). Finally, some participants raised concerns that a frequent testing regimen 414 would lead to employees increasing risky behavior that could result in more COVID-19 415 transmission (Opportunity cost 9, 10). 416

417 4.0 Discussion

418

419 As the COVID-19 pandemic continues to evolve with the emergence of new variants (18,19), 420 waning vaccine and natural immunity (20–22), advancements and setbacks in treatment options 421 (23), and changing human behavior in response to these inputs (24,25), new strategies for 422 controlling and adapting to COVID-19 are needed. The Delta and Omicron variants have 423 brought heightened interest in at-home antigen self-testing and the Biden administration has 424 responded with significant resources to rapidly increase the availability of antigen tests in the 425 US beginning late January 2022. The extent to which this intervention will have a significant 426 public health impact remains to be seen but will in part depend on whether, and if so, how, 427 Americans will use these tests. However as of January 2022, to our knowledge no studies have

428 examined the acceptability of self-testing for COVID-19, including serial testing regimens that429 have been shown most effective at detecting cases.

430

Our mixed-methods study on the acceptability of a serial testing regimen showed that daily
testing using an at-home antigen COVID-19 test was acceptable in one employment context.
Employees were willing and able to adhere to a daily testing regimen for up to 21 days, with
75% of participants achieving adherence 90% or greater. In addition to reporting overall high
acceptability and adherence, our study identified three key implementation challenges that must
be addressed for antigen tests to reach their full public health potential.

437

438 First, there is a significant need for educational campaigns to build lay user trust in the accuracy 439 of at-home antigen tests and knowledge around when and how to use them, including how to 440 act on test results (26). Of the seven constructs that comprise acceptability, coherence and 441 perceived effectiveness were most salient and determined whether participants ultimately felt it 442 "was worth it" to test for COVID-19 daily. Importantly with respect to coherence, participants 443 expressed a willingness to tolerate burden (inconvenience, invasiveness), opportunity costs 444 (time), threats to ethicality (loss of privacy) associated with daily testing when they perceived the 445 threat of COVID-19 to be high (high coherence), but indicated that given testing fatigue, this 446 tolerance would not last forever. In the face of declining cases and universal access to 447 vaccination among adults, participants saw a time in the then near future when this testing 448 frequency would no longer be necessary, rendering the intervention less acceptable. As shown 449 in Figure 1, the study was implemented right before the emergence of the Delta variant when 450 case numbers were decreasing, vaccination eligibility was extended to study participants, and 451 the fear of COVID was palpably receding in the public domain and among our study 452 participants. Respondents reported that daily at-home testing made less sense at this moment 453 in the epidemic than it had one month earlier when case numbers were rising and vaccinations

454 were not yet approved. These findings highlight that people's tolerance for testing intensities 455 change based on their changing perceptions of risk. Users urgently need clear public health 456 guidance around when and how frequently to use at-home antigen tests under different 457 epidemiological conditions, including specific guidance around on- and off-ramps to different 458 testing intensities (27).

459

460 We also found that trust in the accuracy of the at-home antigen test was key to whether 461 participants perceived that the intervention would be effective. While most participants reported 462 trusting the results of the test, this trust was primarily grounded in trust in the institutions 463 providing this test and not in scientific evidence supporting test accuracy. Yet given that antigen 464 tests will be distributed and used outside of the employment context, educational campaigns are 465 needed to build trust in the tests, including by increasing lay user knowledge about the accuracy 466 of antigen tests for detecting when users are most infectious and able to transmit to others. 467 Increasing user literacy around antigen testing for COVID-19 may be particularly important 468 given emerging mixed evidence about the performance and accuracy of antigen tests with the 469 Omicron variant, including concerns about tests being less sensitive (28-31) and slower to 470 detect COVID-19 in the nose compared to other sites (32), which may erode trust in antigen 471 tests and impact acceptability and adherence to testing regimens. This work will need to be 472 ongoing and responsive to emerging information with each new variant and delivered across all 473 communities to ensure that scale up antigen testing does not exacerbate existing health 474 disparities (7,33).

475

Second, we wish to highlight that any frequent testing campaign will generate an enormous
amount of sensitive health data and there is currently no existing universal infrastructure for
routinely capturing or reporting this information to relevant health authorities, health care
providers, or institutions (e.g., employers, schools). The lack of a universal recording and

480 reporting system for at-home antigen test results that are test brand agnostic creates numerous 481 challenges including 1) potentially biased statistics around COVID-19 infection rates due to 482 millions of home antigen test results not being reported, with implications for public health 483 surveillance and resource allocation (34-36); 2) sharing of COVID-19 test results through non-484 secure channels (e.g., text messages, emails) providing opportunities for privacy breaches (37-485 39); and 3) challenges for the delivery of anti-viral treatments for COVID-19 within three days 486 after symptom-onset for maximum benefit, due to the lack of guidance on whether a positive 487 home antigen test can be used to gualify for treatment (40,41). In our study, testing data was 488 captured securely and systematically using a mobile app that recorded and interpreted the test 489 result for the user; these data were only shared with the study team, but the app could be 490 further developed to support secure sharing with other entities. Most participants in our study 491 found the app to be acceptable, however using this app was not without challenges, and some 492 participants experienced significant difficulty using the app daily due to lack of internet or smart 493 phone operating system too old to support the app. In a less technology savvy population, 494 comfort with smart phone technology may also be a significant barrier. Further, while nearly all 495 participants were comfortable with tests results being shared with the research team and their 496 employer, they expressed significant concern about results being shared with health or 497 government entities aside from their own provider.

498

Anticipating potentially more dangerous pandemics in the near future, the Biden administration has developed a five-pillar plan for pandemic preparedness that includes "transforming our medical defense [through] dramatically improving diagnostics" (Pillar 1) and "ensuring situational awareness about infectious disease threats for both early warning and real-time monitoring" (Pillar 2) (42). A connected at-home antigen test that could accurately capture tests results and share them with government and health authorities in real time would address both pillars, however significant work remains to be done to build public trust and acceptability in such a

506 system (43). Within the current pandemic, anecdotally, antigen test results are already being 507 informally shared with institutions like schools and employers to support strategies like "test to 508 stay" (testing to remain after exposure) and "test to return" (testing to end isolation or return 509 after infection). To our knowledge, there has been little to no research done on how these 510 results are currently being shared or stored; guidelines for best practices are urgently needed. 511

512 Finally third, given that the COVID-19 and future pandemics may disproportionally and 513 negatively affect low-income and marginalized communities, it is essential that serial testing 514 interventions in the workplace and elsewhere be employed in ways that put equity at the 515 forefront. Mandatory workplace testing policies have the potential to both protect the most 516 vulnerable, front-line employees, but if instituted without proper protections, can also create 517 negative unintended consequences that may disproportionately burden vulnerable populations. 518 The acceptability of a daily testing regimen in this study population was likely influenced by the 519 employment context, including already established norms around routine COVID-19 testing, and 520 job security and benefits (e.g., health insurance, dedicated paid COVID-19 sick leave) available 521 to participants in our study who were all employed full-time. Although we anticipated and probed 522 for worries about job security or loss of income due to testing positive for COVID-19, 523 hypothesizing that this could reduce acceptability and adherence to the intervention, no 524 participants reported such concerns. Possibly because of their job security, participants also 525 almost universally believed that mandatory COVID-19 testing in the workplace was ethical. In 526 other employment contexts with less job and income protection, mandatory serial testing may 527 be much less acceptable and could have harmful unintended consequences.

528

529 **5.0 Conclusion**

530

531 Our study contributed to the knowledge gap around the implementation of serial at-home rapid 532 antigen testing regimens. This is the first study to our knowledge to evaluate the acceptability of 533 a serial COVID-19 testing regimen with a connected test in an employment context and report 534 on adherence to the intervention. Our study advanced the Theoretical Framework of 535 Acceptability by developing quantitative measures of acceptability and identifying three critical 536 barriers to the successful implementation of rapid antigen testing as a public health intervention. 537

538 There were also a number of limitations. The study was implemented at a time of relatively low 539 COVID worry as the number of cases was falling steeply and vaccines offered a promise of 540 durable protection. This epidemiological context along with the COVID-19 vaccine exclusion 541 criterion impacted our ability to enroll a larger number of study participants and limits the 542 generalizability of the findings and our ability to reach saturation. However, low accrual 543 highlighted that context is an understudied component of acceptability causing acceptability to 544 vary across time. Generalizability may also be limited by the fact that the small study was 545 conducted in Southern California in a politically liberal area with high support for COVID 546 precautions and within a stable employment context. Participants were all fully employed at a 547 large company (Disney), and race, education, and SES are not representative of the broader 548 US population. The relatively high adherence to the intervention we report is likely an artifact of 549 the study context and selection bias based on willingness to enroll in the parent daily testing 550 study and participate in in-depth interviews about the experience; we would expect adherence 551 to be lower in the real world. Finally, we only looked at serial testing in an employment setting, 552 although serial testing has now been rolled out in other contexts. Additional studies are needed 553 to build the evidence-base about the acceptability of and adherence to serial-testing regimens to 554 evaluate their public health contribution to interrupting transmission.

555

556

557 Works Cited

558

- 5591.Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, et al. Test sensitivity is560secondary to frequency and turnaround time for COVID-19 screening. Sci Adv. 2021 Jan
- 561 1;7(1).
- 2. Ricks S, Kendall EA, Dowdy DW, Sacks JA, Schumacher SG, Arinaminpathy N.
- 563 Quantifying the potential value of antigen-detection rapid diagnostic tests for COVID-19: a 564 modelling analysis. BMC Med. 2021 Dec 1;19(1):1–13.
- 565 3. McKay SL, Tobolowsky FA, Moritz ED, Hatfield KM, Bhatnagar A, LaVoie SP, et al.
- 566 Performance Evaluation of Serial SARS-CoV-2 Rapid Antigen Testing During a Nursing

567 Home Outbreak. Ann Intern Med. 2021 Jul 1;174(7):945–51.

- 568 4. Smith RL, Gibson LL, Martinez PP, Ke R, Mirza A, Conte M, et al. Longitudinal
- 569 Assessment of Diagnostic Test Performance Over the Course of Acute SARS-CoV-2
- 570 Infection. J Infect Dis [Internet]. 2021 Sep 17 [cited 2022 Feb 2];224(6):976–82. Available

571 from: https://academic.oup.com/jid/article/224/6/976/6311835

- 572 5. Surasi K, Cummings KJ, Hanson C, Kate Morris M, Salas M, Seftel D, et al. Effectiveness
- 573 of Abbott BinaxNOW Rapid Antigen Test for Detection of SARS-CoV-2 Infections in
- 574 Outbreak among Horse Racetrack Workers, California, USA Volume 27, Number 11—
- 575 November 2021 Emerging Infectious Diseases journal CDC. Emerg Infect Dis
- 576 [Internet]. 2021 Nov 1 [cited 2022 Feb 2];27(11):2761–7. Available from:
- 577 https://wwwnc.cdc.gov/eid/article/27/11/21-1449_article
- 578 6. Paltiel AD, Zheng A, Walensky RP. Assessment of SARS-CoV-2 Screening Strategies to
- 579 Permit the Safe Reopening of College Campuses in the United States. JAMA Netw open
- 580 [Internet]. 2020 Jul 31 [cited 2022 Feb 2];3(7). Available from:
- 581 https://pubmed.ncbi.nlm.nih.gov/32735339/
- 582 7. Dawson L, Kates J. Rapid Home Tests for COVID-19: Issues with Availability and Access

- in the U.S. [Internet]. Kaiser Family Foundation. 2021 [cited 2022 Feb 2]. Available from:
- 584 https://www.kff.org/report-section/rapid-home-tests-for-covid-19-issues-with-availability-
- 585 and-access-in-the-u-s-issue-brief/
- S86
 Crozier A, Rajan S, Buchan I, McKee M. Put to the test: use of rapid testing technologies
 for covid-19. BMJ. 2021 Feb 3;372.
- 588 9. GOV.UK. Order coronavirus (COVID-19) rapid lateral flow tests [Internet]. 2022 [cited
- 589 2022 Feb 2]. Available from: https://www.gov.uk/order-coronavirus-rapid-lateral-flow-tests
- 590 10. The White House. Fact Sheet: The Biden Administration to Begin Distributing At-Home,
- 591 Rapid COVID-19 Tests to Americans for Free [Internet]. 2022 [cited 2022 Feb 2].
- 592 Available from: https://www.whitehouse.gov/briefing-room/statements-
- 593 releases/2022/01/14/fact-sheet-the-biden-administration-to-begin-distributing-at-home-
- 594 rapid-covid-19-tests-to-americans-for-free/
- 595 11. The White House. Press Briefing by White House COVID-19 Response Team and Public
 596 Health Officials [Internet]. 2021 [cited 2022 Feb 2]. Available from:
- 597 https://www.whitehouse.gov/briefing-room/press-briefings/2021/10/06/press-briefing-by-
- 598 white-house-covid-19-response-team-and-public-health-officials-60/
- 599 12. The White House. President Biden's COVID-19 Plan [Internet]. 2021 [cited 2022 Feb 2].
 600 Available from: https://www.whitehouse.gov/covidplan/
- Balas E, Boren S. Managing Clinical Knowledge for Health Care Improvement. Yearb
 Med Inform. 2000;1:65–79.
- 603 14. Grant J, Green L, Mason B. Basic research and health: a reassessment of the scientific
- basis for the support of biomedical science. Res Eval [Internet]. 2003 Dec 1 [cited 2022]
- 605 Feb 2];12(3):217–24. Available from:
- 606 https://academic.oup.com/rev/article/12/3/217/1535438
- 15. Morris ZS, wooding S, Grant J. The answer is 17 years, what is the question:
- 608 understanding time lags in translational research. J R Soc Med [Internet]. 2011 Dec [cited

609		2022 Feb 2];104(12):510–20. Available from: https://pubmed.ncbi.nlm.nih.gov/22179294/
610	16.	Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: An
611		overview of reviews and development of a theoretical framework. BMC Health Serv Res.
612		2017;
613	17.	King N. Doing Template Analysis. Qual Organ Res Core Methods Curr Challenges. 2017
614		Dec 9;426–50.
615	18.	Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, et al. Rapid
616		epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022
617		Jan 7;
618	19.	Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes
619		among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern
620		California. MedRxiv Prepr [Internet]. 2022 Jan 11 [cited 2022 Feb 3]; Available from:
621		https://www.medrxiv.org/content/10.1101/2022.01.11.22269045v1
622	20.	Rössler A, Riepler L, Bante D, von Laer D, Kimpel J. SARS-CoV-2 Omicron Variant
623		Neutralization in Serum from Vaccinated and Convalescent Persons. N Engl J Med. 2022
624		Jan 12;
625	21.	Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Eg Al Ly HT, et al. Omicron
626		extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature.
627		2021;602:654–656.
628	22.	Straten K van der, Guerra D, Gils MJ van, Bontjer I, Caniels TG, Willigen HDG van, et al.
629		Mapping the antigenic diversification of SARS-CoV-2. MedRxiv Prepr [Internet]. 2022 Jan
630		3 [cited 2022 Feb 3]; Available from:
631		https://www.medrxiv.org/content/10.1101/2022.01.03.21268582v1
632	23.	Annavajhala MK, Mohri H, Wang P, Nair M, Zucker JE, Sheng Z, et al. Emergence and
633		expansion of SARS-CoV-2 B.1.526 after identification in New York. Nature. 2021 Aug
634		24;597(7878):703–8.

- 635 24. Schneider CR, Dryhurst S, Kerr J, Freeman ALJ, Recchia G, Spiegelhalter D, et al.
- 636 COVID-19 risk perception: a longitudinal analysis of its predictors and associations with
- health protective behaviours in the United Kingdom. J Risk Res [Internet]. 2021 [cited
- 638 2022 Feb 3];24(3–4):294–313. Available from:
- 639 https://www.tandfonline.com/doi/abs/10.1080/13669877.2021.1890637
- 640 25. Qin H, Sanders C, Prasetyo Y, Syukron M, Prentice E. Exploring the dynamic
- 641 relationships between risk perception and behavior in response to the Coronavirus
- Disease 2019 (COVID-19) outbreak. Soc Sci Med [Internet]. 2021 Sep 1 [cited 2022 Feb
- 643 3];285. Available from: https://pubmed.ncbi.nlm.nih.gov/34388619/
- 644 26. Woloshin S, Dewitt B, Krishnamurti T, Fischhoff B. Assessing How Consumers Interpret
- and Act on Results From At-Home COVID-19 Self-test Kits: A Randomized Clinical Trial.
- 546 JAMA Intern Med [Internet]. 2022 Jan 31 [cited 2022 Feb 21]; Available from:
- 647 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2788656
- 648 27. Peeling RW, Heymann DL, Teo Y-Y, Garcia PJ. Diagnostics for COVID-19: moving from
- 649 pandemic response to control. Lancet [Internet]. 2022 Feb 19 [cited 2022 Feb
- 650 23];399(10326):757–68. Available from:
- 651 http://www.thelancet.com/article/S0140673621023461/fulltext
- 652 28. Adamson B, Sikka R, Wyllie AL, Premsrirut P. Discordant SARS-CoV-2 PCR and Rapid
- Antigen Test Results When Infectious: A December 2021 Occupational Case Series.
- 654 MedRxiv Prepr [Internet]. 2022 Jan 5 [cited 2022 Feb 3]; Available from:
- 655 https://www.medrxiv.org/content/10.1101/2022.01.04.22268770v1
- 656 29. Schrom J, Marquez C, Pilarowski G, Wang G, Mitchell A, Puccinelli R, et al. Direct
- 657 Comparison of SARS-CoV-2 Nasal RT-PCR and Rapid Antigen Test (BinaxNOW[™]) at a
- 658 Community Testing Site During an Omicron Surge. medRxiv [Internet]. 2022 Jan 19 [cited
- 659 2022 Feb 3];2022.01.08.22268954. Available from:
- 660 https://www.medrxiv.org/content/10.1101/2022.01.08.22268954v4


- 661 30. FDA. Omicron Variant: Impact on Antigen Diagnostic Tests (As of 12/28/2021) [Internet].
- 662 2021 [cited 2022 Feb 3]. Available from: https://www.fda.gov/medical-
- 663 devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-
- 664 covid-19-tests#omicronvariantimpact
- 665 31. Bekliz M, Adea K, Alvarez C, Essaidi-Laziosi M, Escadafal C, Kaiser L, et al. Analytical
- sensitivity of seven SARS-CoV-2 antigen-detecting rapid tests for Omicron variant.
- 667 MedRxiv Prepr [Internet]. 2021 Dec 22 [cited 2022 Feb 3]; Available from:
- 668 https://www.medrxiv.org/content/10.1101/2021.12.18.21268018v1
- 669 32. Marais G, Hsiao N, Iranzadeh A, Doolabh D, Enoch A, Chu C, et al. Saliva swabs are the
- 670 preferred sample for Omicron detection. MedRxiv Prepr [Internet]. 2021 Dec 24 [cited
- 671 2022 Feb 3]; Available from:
- 672 https://www.medrxiv.org/content/10.1101/2021.12.22.21268246v1
- 33. Bilal U, Tabb LP, Barber S, Diez Roux A V. Spatial Inequities in COVID-19 Testing,
- 674 Positivity, Confirmed Cases, and Mortality in 3 U.S. Cities : An Ecological Study. Ann
- 675 Intern Med. 2021 Jul 1;174(7):936–44.
- 676 34. McLaughlin K. Growing use of home COVID-19 tests leaves health agencies in the dark
- about unreported cases [Internet]. PBS News Hour. 2021 [cited 2022 Feb 23]. Available
- 678 from: https://www.pbs.org/newshour/health/growing-use-of-home-covid-19-tests-leaves-
- 679 health-agencies-in-the-dark-about-unreported-cases


680 35. Kasakove S. At-Home Covid Tests Raise Questions About Accurately Counting Cases

- 681 [Internet]. The New York Times. 2021 [cited 2022 Feb 23]. Available from:
- 682 https://www.nytimes.com/2021/12/30/us/at-home-rapid-covid-tests-cases.html
- 36. Jean S, Burnham C-AD, Chapin K, Garner OB, Pai NP, Turabelidze G, et al. At-Home
- 684 Testing for Infectious Diseases: The Laboratory Where You Live. Clin Chem [Internet].
- 685 2022 [cited 2022 Feb 18];68(1):19–26. Available from:
- 686 https://academic.oup.com/clinchem/article/68/1/19/6490224

- 687 37. Brennan Center for Justice. Evaluating the Privacy of Covid-19 At-Home Tests [Internet].
- 688 2021 [cited 2022 Feb 3]. Available from: https://www.brennancenter.org/our-
- 689 work/analysis-opinion/evaluating-privacy-covid-19-home-tests
- 690 38. U.S. Equal Employment Opportunity Commission. What You Should Know About COVID-
- 19 and the ADA, the Rehabilitation Act, and Other EEO Laws [Internet]. 2021 [cited 2022]
- 692 Feb 3]. Available from: https://www.eeoc.gov/wysk/what-you-should-know-about-covid-
- 693 19-and-ada-rehabilitation-act-and-other-eeo-laws
- 694 39. Ribeiro-Navarrete S, Saura JR, Palacios-Marqués D. Towards a new era of mass data
- 695 collection: Assessing pandemic surveillance technologies to preserve user privacy.
- Technol Forecast Soc Change [Internet]. 2021 Jun 1 [cited 2022 Feb 23];167:120681.
- 697 Available from: /pmc/articles/PMC8019834/
- 40. CDC. Self-Testing [Internet]. 2022 [cited 2022 Feb 3]. Available from:
- 699 https://www.cdc.gov/coronavirus/2019-ncov/testing/self-testing.html
- 41. Wroe EB, Seung KJ, Baker BK, Farmer PE. Test and treat: a missing link in the global
- fight against COVID-19. Lancet Glob Heal [Internet]. 2022 Feb 1 [cited 2022 Feb
- 702 23];10(2):e181–2. Available from:
- 703 http://www.thelancet.com/article/S2214109X21005684/fulltext
- 704 42. The White House. American Pandemic Preparedness: Transforming Our Capabilities.
 705 2021;
- 43. Kadam R, White W, Banks N, Katz Z, Dittrich S, Kelly-Cirino C. Target Product Profile for
- a mobile app to read rapid diagnostic tests to strengthen infectious disease surveillance.
- 708 PLoS One [Internet]. 2020 Jan 1 [cited 2022 Feb 3];15(1). Available from:
- 709 https://pubmed.ncbi.nlm.nih.gov/31995628/

COVID-19 Pandemic Context Timeline





Figure